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Abstract
Background and aims—Guidelines recommend screening for gastroesophageal varices.
Regional studies suggest screening is underutilized, but information from across the United States
is unavailable. We explored practice patterns and adherence to guidelines in a random sample of
physicians and sought to define whether differences existed according to practice type, setting and
years of practice.
Materials and Methods—Surveys were randomly sent to 600 gastroenterologists and
hepatologists. Descriptive data is presented as percentage and comparisons were performed by
chi-square analysis. Significance was defined at a p value <0.05.
Results—180 completed surveys were returned. Mean age was 48.9 ± 10 years and 87% were
male. 50% were community-based and 74% had been in practice >10 years. 53% (78%
hepatologists versus 45% of gastroenterologists) screened consistently (>75% of the time), (p <
0.001). No differences in screening frequency were found according to practice setting or years in
practice. 62% screened all cirrhotics whereas 38% screened based on clinical characteristics. In
patients without gastroesophageal varices, 60% repeated esophagogastroduodenoscopy in 2–3
years. In those with small gastroesophageal varices, repeat esophagogastroduodenoscopy was
recommended in 1–2 years by 73%. In patients with small and large varices, 40% and 54% of
physicians respectively, recommended prophylaxis. 6% of physicians recommend prophylaxis
regardless of the presence or size of varices.
Conclusions—Screening for varices is under-implemented. Many screened based on clinical
findings that have not been shown to reliably predict high-risk gastroesophageal varices.
Continued education and removal of financial barriers to screening are central to increasing
screening rates and improving patient outcomes.
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Haemorrhage from gastroesophageal varices (GEV) is the most lethal complication of
cirrhosis and portal hypertension. Variceal bleeding (VB) occurs in 25–40% of patients with
cirrhosis and each episode of bleeding is associated with a 10–30% mortality rate [1,2] In
light of the frequency with which VB occurs in patients with cirrhosis and the high rate of
mortality associated with each bleeding episode, prevention of bleeding is an important goal
in the management of patients with cirrhosis.
Primary prophylaxis, through both pharmacological and endoscopic means, reduces the
incidence of variceal haemorrhage in patients with cirrhosis. Multiple studies have shown
that beta-blockers reduce the risk of bleeding by nearly 50% [3,4] While there are recent
data that beta-blockers reduce bleeding when given to patients with small varices [5], most
studies only demonstrate a benefit of primary prophylaxis for patients with large varices,
and some specifically show no benefit of primary prophylaxis for patients with small or no
varices [4,6].
In order to prevent variceal bleeding in patients with cirrhosis, those patients at highest risk
for bleeding must be identified. Clinical signs and symptoms such as ascites,
thrombocytopenia, splenomegaly and Child-Pugh class do not adequately predict which
patients will bleed [7–10]. Thus, the American College of Gastroenterology (ACG) and the
American Association for the Study of Liver Disease (AASLD) have published guidelines
recommending screening esophagogastroduodenoscopy (EGD) for GEV [11,12]. The initial
guidelines, published in 1997 and 1998, recommended that once patients with large varices
are identified, institution of primary prophylaxis is initiated. More recently, the 2007
guidelines have become more flexible in regard to initiating primary prophylaxis in patients
with small varices with certain high-risk stigmata [13]. The recommendation to screen all
cirrhotics without regard to clinical or laboratory findings remained, however.
While patients with large varices are started on lifelong primary prophylaxis, those with
small or no varices must be monitored through surveillance endoscopy to assess the future
risk of bleeding. The same guidelines that endorse universal screening for varices also
recommend continued surveillance for varices; with repeat endoscopic surveillance
recommended at 2–3 year intervals for the patients without GEV and 1–2 years for patients
with small GEV.
Even though the guidelines for screening and the use of primary prophylaxis were originally
published by the ACG and AASLD in 1997 and 1998, respectively, findings of regional
studies, have shown that screening is underutilized [14,15]. There are no data regarding
screening for high-risk varices and the institution of primary prophylaxis from across the
U.S. or internationally. Thus, we explored practice patterns in a random sample of U.S.
gastroenterologists and hepatologists. We examined whether differences exist in screening,
surveillance and institution of primary prophylaxis between physicians in academic versus
community practice, physicians who describe themselves as primarily gastroenterologists
versus primarily hepatologists, and the physicians’ number of years in practice.
2. Materials and methods
2.1. Study design
We conducted a national cross-sectional survey of academic and community
gastroenterologists and hepatologists in the United States using a self-administered
questionnaire (Appendix A). The survey was conducted between August 2003 and
November 2003. Eligible participants had graduated from their training programme and
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were members of either the ACG or the AASLD. These two organizations were chosen in an
effort to sample equal numbers of hepatologists and gastroenterologists. We used a random
numbers generator to select 300 members of each of the above professional organizations.
2.2. Survey distribution
The survey (Appendix A), along with a cover letter explaining the goals of our project, was
initially sent via facsimile to a random sample of 600 gastroenterologists and hepatologists
in August 2003. We allowed a four-week response period for data collection and then re-
faxed the survey. Responses from partially completed questionnaires were not included in
the analysis.
2.3. Statistical analysis
The collected data were analysed using the Statistical Analysis Software (SPSS 11.0, SPSS
Inc., Chicago, IL). Descriptive data were presented as percentages and comparisons were
performed by chi-square analysis or Fisher’s exact test if applicable. Significance was
defined at a p value ≤0.05.
3. Results
A total of 600 surveys were sent to randomly selected physicians and 191 questionnaires
were returned (32%). 180 (30%) questionnaires were completed in their entirety whereas, 11
questionnaires were returned only partially completed and, as stated above, data derived
from these were not included in the final analysis.
3.1. Demographic data
Respondent data is depicted in Table 1. The mean age of the physicians was 48.9 ± 10 years
and 87% of them were male. 50% physicians were based in the community (private practice)
and 74% had been in practice for more than 10 years. 72% physicians describe themselves
as gastroenterologists primarily, and 28% of them as hepatologists primarily. Overall, 37
states were represented with the greatest number of responses coming from New York (17),
California (16), and Texas (12). Responses were also divided by region; there were 64
(36%) responses from the Northeast, 65 (36%) responses from the Southeast, 38 (21%)
responses from the Northwest, and 13 (7%) responses from the Southwest.
As the responses to the survey were anonymous, we could not perform comparisons on all
demographic variables between physicians that responded versus those that did not.
However, we were able to ascertain if differences existed between the group as a whole and
“responders” on certain variables. The gender and regional distribution of all survey
recipients were recorded based on names and area codes. Overall, 91% of the physicians
who were faxed a survey were male versus 87% of responders (p = NS). Regional
distribution also did not differ significantly from the responders; 41% of the surveys were
faxed to the Northeast region (36% of responders), 31% to the Southeast (36% of
responders), 19% to the Northwest (21% of responders) and 9% to the Southwest (7% of
responders) (p = NS).
3.2. Initial screening patterns—overall frequency of screening
Physicians were asked to estimate how often they screen for varices in patients with
cirrhosis without a history of prior bleeding. Only the physicians who screened consistently
(defined as greater than 75% of the time) were counted as positive responses; 53% of them
met these criteria (n = 95). Overall, by quartile, 53% physicians screened more than 75% of
the time. 23% physicians screened between 50 and 75% of the time, 18% screened less than
50% of the time and 5% never screened.
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Comparisons were made between those who consistently screen versus those who do not
screen consistently (Table 2). No differences were observed within practice setting and years
in practice. Hepatologists screened more consistently than gastroenterologists (78% vs. 45%,
p < 0.001).
3.3. Initial screening patterns—types of patients screened
The physicians who did report screening for varices at any point (i.e. frequency of screening
anywhere from 1 to 100%, n = 171) were asked whether they screened all patients with
cirrhosis or they screened only according to certain clinical characteristics. Overall, 106 of
171 physicians (62%) reported that they screened all cirrhotics, whereas 38% physicians
screened certain patients only on the basis of clinical signs and symptoms. There were no
statistically significant differences among practice type, setting and years in practice. Those
who screened only by clinical signs and symptoms reported the following as reasons to
screen (more than one response was allowed): Child-Pugh class B/C 65%, ascites 50%,
splenomegaly 47%, telangectasia 12%, thrombocytopenia 55%, and other 7% (Fig. 1).
The comparison of physicians by practice type who screened selectively by clinical signs
and symptoms showed significantly more hepatologists use thrombocytopenia as an
indication for screening EGD (p = 0.03).
When the responses to overall frequency of screening were compared with the responses to
the types of patients screened, 76% (n = 72) of the consistent screeners (screening in greater
than 75% of cirrhotics) actually screened all cirrhotics regardless of the presence of certain
clinical signs and symptoms. Thus, overall, only 40% of all physicians surveyed screen
consistently and screen all patients with cirrhosis.
3.4. Surveillance patterns: no varices
The surveyed physicians were asked at what interval they would perform surveillance
endoscopy in a patient with no varices. Overall, less than 1% physicians replied six-month
intervals, 20% replied 1-year intervals, 41% replied 2-year intervals, 19% replied 3-year
intervals, and 20% replied greater than 3-year intervals.
3.5. Surveillance patterns: small varices
The surveyed physicians were asked at what interval they would perform surveillance
endoscopy in a patient with small varices. Overall, 5% physicians replied six-month
intervals, 48% replied 1-year intervals, 25% replied 2-year intervals, 10% replied 3-year
intervals, and 12% replied greater than 3-year intervals.
3.6. Initiation of primary prophylaxis
When the surveyed physicians were asked when they would start primary prophylaxis, the
overall responses were: 6% would start primary prophylaxis in patients regardless of the
presence or absence of varices, 40% in patients with small (less than 7 mm) varices at
endoscopy and 54% in patients with large (greater than 7 mm) varices at endoscopy.
The data comparing the timing of primary prophylaxis are shown in Table 3. Significantly
more hepatologists initiated primary prophylaxis for large varices only (p < 0.001).
Significant differences were found by geographical analysis as well; more physicians from
the Northwest initiated primary prophylaxis for large varices only when compared to other
regions (p = 0.048).
Barritt and Arguedas Page 4













3.7. Responders definition of primary prophylaxis and actual primary prophylaxis
instituted
When asked what the definition of primary prophylaxis was to them, in a format that
allowed multiple answers, the surveyed physicians stated the following: 86.1% identified
beta-blockers as primary prophylaxis; endoscopic variceal ligation (EVL), 28.3%; beta-
blockers and EVL, 25.6%; nitrates, 11.7%; sclerotherapy, 5.0%; sclerotherapy and beta-
blockers, 3.3%; beta-blockers and nitrates, 20.0%; one responder selected “other” and
entered “portosystemic shunt”, 0.6%.
More academicians than community physicians identified endoscopic variceal ligation as a
form of primary prophylaxis (36% vs. 21%, p = 0.025). More physicians with less than or
equal to 10 years’ experience identified EVL (42% vs. 20%, p = 0.017) or EVL plus beta-
blockers (42% vs. 24%, p = 0.03) as primary prophylaxis. There were also regional
differences as more physicians in the Northwest and Southwest identified sclerotherapy
(23% in SW vs. 2–5% in other regions, p = 0.014) and variceal ligation (46% in SW, 42% in
NW vs. 22–23% in other regions, p = 0.05) as forms of primary prophylaxis.
Overall, the primary prophylaxis actually employed by the responding physicians were:
beta-blockers, 84%; EVL, 6%; beta-blockers and EVL, 7%; nitrates, 1%, sclerotherapy
0.6%, beta-blockers and sclerotherapy, 0.6%; beta-blockers and nitrates, 0.6%.
Significantly more academicians used beta-blockers as primary prophylaxis. More
hepatologists used EVL. Physicians in practice less than or equal to 10 years were more
likely to use a combination of EVL and beta-blockers (17% vs. 3%, p = 0.004) or nitrates
(4% vs. 0%, p = 0.018) as primary prophylaxis.
3.8. Limitations to adherence with published guidelines
In the final question of the survey, physicians were asked whether there were any specific
limitations or barriers to screening for GEV. The question allowed for multiple answers.
18.9% cited a lack of third party payer reimbursement; 8.9% were unfamiliar with the
practice guidelines; 20% were uncertain about the benefit of primary prophylaxis; 20% cited
the poor clinical features that predict GEV; 13.9% gave other responses.
Subgroup analysis showed several significant differences in barriers to screening. More
community physicians were unfamiliar with the guidelines (14% vs. 3%, p = 0.01). More
gastroenterologists were unfamiliar with guidelines as well (12% vs. 0%, p = 0.01).
Physicians with greater than 10 years’ experience were more likely to question the benefits
of screening (11% vs. 4%, p = 0.05). Regional analysis showed that cost was a barrier in the
Northeast and Southwest (28% and 31% respectively vs. 11–12% in other regions, p = 0.04).
4. Discussion
According to project estimates, the number of patients with cirrhosis is expected to rise as a
result of hepatitis C and due to the effects of non-alcoholic fatty liver disease [16,17]. As a
consequence of the increasing development of end-stage liver disease, the morbidity and
mortality associated with complications from hepatocellular dysfunction and portal
hypertension will be considerable. As “curative” treatment options for well-established
cirrhosis are generally not available, therapeutic interventions usually focus on its
complications after they have developed. Therefore, prevention is a cornerstone in the
management of patients with cirrhosis. One such intervention, screening for high-risk
varices, has been recommended by the ACG and the AASLD [11–13] Screening and
surveillance for high-risk varices according to the published guidelines has been shown to be
a cost-effective intervention [18]. Therefore, given the efficacy of primary prophylaxis [19]
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and the economical feasibility of screening, we would expect that the majority of
practitioners embrace such a preventive strategy.
However, several regional studies had suggested that, despite these guidelines, screening for
varices is under-implemented [20] Arguedas et al. [14] found that among patients presenting
for liver transplant evaluation, only 46% had undergone any type of screening (endoscopic
or radiological). Zaman et al. found that “screening for varices” was the major indication for
EGD only 1.5% of the time according to the Clinical Outcomes Research Initiative [21]
These studies, though, examined a limited number of patients who were prone to potential
referral-bias owing to their regional nature. Their methodology did not permit an adequate
understanding as to practice patterns of treating physicians and potential barriers to
screening.
This study is the first to examine physician practice patterns across the United States in
regard to screening for varices and implementation of primary prophylaxis. Members of two
U.S.-based professional organizations (ACG and AASLD) were surveyed regarding their
practice patterns concerning screening, surveillance and primary prophylaxis for GEV. Our
response rate was considered adequate with 180 of 600 physicians (30%) completing the
entire questionnaire [22] In addition, there was consistency among the responses, which
supports the fact that the results are representative of the current practice patterns of
screening for varices and implementation of primary prophylaxis in the United States.
The most significant finding of our study is that only 53% of physicians consistently screen
patients with cirrhosis. Of these, 76% screen all cirrhotics and 24% screen only if there are
clinical or laboratory indicators suggesting portal hypertension; 5% of physicians never
recommend screening at all. Therefore, only 40% of physicians adhere to published
recommendations leaving a large proportion of patients with high-risk varices that are not
identified, and therefore, remain unprotected.
When comparisons were made between physicians who consistently screen and those who
do not, there was a statistically significant higher proportion of hepatologists who
recommended screening compared to gastroenterologists (78% vs. 45%, respectively). We
speculate this may be due, in part, to greater familiarity with published guidelines as no
hepatologists responded to a “lack of awareness” as a barrier to screening, whereas 12% of
gastroenterologists did. In addition, academic physicians were more familiar with practice
guidelines. This could be related to the fact that most hepatologists practice in the academic
setting. “Lack of reimbursement” was cited by 20% of physicians as a potential barrier for
screening. According to data from our institution, pre-certification prior to EGD is usually
not necessary in patients with cirrhosis, thus, the procedure is usually reimbursed.
In patients in whom an initial endoscopy did not reveal varices, surveillance patterns did not
differ significantly according to practice type and setting, years in practice and geographical
location. A “trend” towards more frequent screening among hepatologists and practitioners
in the Southwestern United States was observed. We do not know the significance of this
finding and it could reflect alpha statistical error. In patients in whom an initial screening
endoscopy revealed small varices, surveillance patterns did not differ significantly according
to practice type and setting or years in practice. Physicians in the Northeastern United States
tended to perform surveillance at greater intervals than physicians in the rest of the country.
Non-selective beta-blockers were recommended as the initial primary prophylaxis modality
by 86% of respondents with the majority of the remaining physicians recommending
endoscopic variceal ligation. Interestingly, we found that primary prophylaxis is instituted in
patients with small varices by the majority of gastroenterologists (49%) whereas the
majority of hepatologists (80%) implemented primary prophylaxis in patients with large
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varices. A recent placebo, controlled study by Merkel et al. [5] found that the use of nadolol
in patients with small varices was associated with a lower “variceal growth rate” (9/83
patients developed large varices) compared to 29 of 78 patients on placebo developing high-
risk varices. In addition, this study found that the risk of a first variceal bleed was
significantly lower in patients on nadolol. These findings contrast with those found by
several authors over the past two decades which have shown the benefit of primary
prophylaxis in patients with large varices [4]. In addition, a recent study demonstrated that
non-selective beta-blockers do not prevent the development of varices in patients with portal
hypertension [6].
These data also are taken into account in the 2007 updated AASLD guidelines. All patients
with cirrhosis should be screened for GEV regardless of clinical signs or symptoms. Primary
prophylaxis is still not recommended to prevent the formation of varices. Non-selective beta-
blockers should be used for high-risk small varices that have not bled. Non-selective beta-
blockers may be used for low risk small varices that have not bled, although the long-term
benefit of this strategy has not been established. EVL should be reserved for large varices
that have a high risk of haemorrhage or large varices in those patients who cannot tolerate a
beta-blocker. Nitrates (alone or with beta-blockers), shunt therapy, or sclerotherapy should
not be used as primary prophylaxis [13].
Our study has several potential limitations. While the study was conducted five years ago,
no studies to reflect current practice have been done since that time, thus these data
represent the most up to date information available in the United States or internationally.
The survey was done with the 1997–1998 guidelines in mind; however, the new guidelines
do not change the overall results or interpretation of the survey, especially in regard to the
lack of screening given to all cirrhotics and the warning against the use of markers for portal
hypertension that are neither sensitive nor specific for varices.
Although this survey data is from American physicians, the guidelines were published in
journals with a widespread international audience. The AASLD and the ACG and their
respective publications, Hepatology and the American Journal of Gastroenterology, reflect
international opinions from international panels of experts. The guidelines were meant to
apply to all healthcare professionals caring for patients with liver disease, regardless of
country of origin and thus the survey results should be of interest to all practitioners.
The label of hepatologist vs. gastroenterologist may contribute to some bias in the survey
responses. A “Hepatologist” was defined as a physician whose patient population consists
mainly of patients with liver disease (Appendix A, question 5). Respondents self-determined
their status. It is possible that those with a greater interest in liver disease were more likely
to define themselves as hepatologists and adhere to the guidelines more closely.
Nevertheless, as the overall number of gastroenterologists significantly outnumbers the
hepatologists in the United States and the majority of patients with cirrhosis are cared for by
community gastroenterologists, the practice patterns of all respondents remain important.
Recently, there has been a Certificate of Added Qualification for Transplant Hepatology
sanctioned by the American Board of Internal Medicine and the advent of transplant
hepatology fellowship programmes. Prior to the 1990’s, formal training in hepatology was
not widespread and expertise was based on clinical and/or research experience. While
scattered hepatology fellowship programmes did exist, their numbers paled in comparison to
gastroenterology training programs [23] Given the average age of the respondents, 49, most
would have finished their fellowships at least 15 years ago, before such dedicated training
was widespread.
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Other limitations within our study are inherent to survey studies in general. First, while the
response rate was only 30%, this is similar or better than response rates achieved in other
published surveys [24–26] More critical than response rate, however, is the degree to which
non-respondents are similar to respondents. Based on the available data, certain
demographic features were similar between all survey recipients and those who chose to
respond. If these groups are dissimilar, a survey study can be biased. Thus, the second
possible limitation of our survey study is that only highly motivated practitioners answered
the questionnaire thereby introducing this bias. In a worst case scenario, physicians may
answer what they “consider correct” as opposed to what they really implement in clinical
practice. Still, these concerns do not explain the relatively low proportion of physicians who
consistently screen for varices. We would expect that introduction of bias would have
“falsely” increased the proportion of physicians who screen. This only serves to underscore
the relative lack of compliance with the established guidelines.
In conclusion, endoscopic screening for varices in patients with cirrhosis in the United
States is under-implemented by both hepatologists and gastroenterologists. Failure to screen
leaves a considerable proportion of patients at risk for variceal bleeding and contributes to
significant morbidity, mortality and healthcare costs. The solution to this problem lies in
continuing medical education for physicians that stresses not only what the guidelines are
but also why primary prophylaxis is vitally important to our patients. Another barrier, third
party payer reimbursement, varies by region and is certainly affected by individual managed
care organizations. This barrier, however, may become an incentive as more managed care
organizations investigate merit pay options and base their reimbursement on compliance
with the established guidelines. Until further information is available regarding whether
pharmacological agents prevent the development and/or growth of varices or until reliable
clinical signs and symptoms accurately predict which patients will bleed, endoscopic
screening for varices remains an acceptable, cost-effective intervention.
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Appendix A
1. What is your age?__________
2. What is your gender?__________
3. In which State do you currently practice?
4. Setting of current practice:
i. Community-based
ii. Academic-based
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5. Type of current practice (>50% of patients seen):
i. Primarily Gastroenterology
ii. Primarily Hepatology
6. Years in practice (since completion of fellowship):
i. Less than or equal to 10 years
ii. Greater than 10 years
7. Do you screen for varices in patients without prior bleeding?
i. Consistently (greater than 75% of the time)
ii. Frequently (between 50–75% of the time
iii. Infrequently (between 1–49% of the time)
iv. Never (Skip questions 8, 9 and 10)
8. Who do you screen for varices?
i. All patients with cirrhosis
ii. Patients with cirrhosis and (circle all that apply)





• other; please specify:






v. Greater than 3 years; please specify:__________
10. In patients with small varices (grade I, less than 7mm), at what interval would





v. Greater than 3 years; please specify:__________
11. When would you institute primary prophylaxis?
i. Regardless of the absence or presence of varices
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ii. Small varices at endoscopy
iii. Large varices at endoscopy (greater than 7 mm)
12. What is your definition of primary prophylaxis (circle all that apply) ?
i. Beta-blockers
ii. Endoscopic variceal ligation
iii. Endoscopic variceal ligation plus beta-blockers
iv. Nitrates
v. Sclerotherapy
vi. Sclerotherapy plus beta-blockers
vii. Beta-blockers and nitrates
viii. Other__________
13. What type of primary prophylaxis do you recommend initially?
i. Beta-blockers
ii. Endoscopic variceal ligation
iii. Endoscopic variceal ligation plus beta-blockers
iv. Nitrates
v. Sclerotherapy
vi. Sclerotherapy plus beta-blockers
vii. Beta-blockers and nitrates
14. What are the major reasons you do not screen for varices (circle all that
apply)?
i. Lack of third-party payer reimbursement
ii. Unfamiliarity about practice guidelines that recommend screening
iii. Uncertainty about benefit of primary prophylaxis
iv. Poor clinical features that predict the presence of varices
v. Other; please specify: __________
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Selective screening: GI vs. Hepatology.
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Completed surveys 180 30a
Age (years) 48.9 ± 10
Sex (Male) 156 87
Practice Setting (Community) 90 50
Practice Type (Primarily Gastroenterologists) 130 72







600 total surveys distributed.
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Table 2
Screening frequency.
Screen consistently (≥75% of the time)a Do not screen consistently/never screena p value
Community 52 48 NS
Academic 56 44
Gastroenterology 45 55 <0.001
Hepatology 78 22
≤ 10 years in practice 63 37 NS
>10 years in practice 51 49





Data are presented as percentages.
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Table 3
Initiation of primary prophylaxis.
Regardless Small varices Large varices p value
Community 7 47 46 NS
Academic 4 33 63
Gastroenterology 7 49 44 <0.001
Hepatology 2 18 80
≤10 years in practice 7 43 50 NS
>10 years in practice 4 33 63
NE 8 33 59 0.048
SE 6 55 39
NW 3 26 71
SW 8 38 54
Data are presented as percentages.
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